Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement

20 Feb 2024

Abstract excerpt

Complement-mediated diseases can be treated using systemic inhibitors. However, complement components are abundant in circulation, affecting systemic inhibitors' exposure and efficacy. Furthermore, because of complement's essential role in immunity, systemic treatments raise infection risk in patients. To address these challenges, we developed antibody fusion proteins combining the alternative-pathway complement...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Complement system in diseases
Share to Renal Diseases and Glomerulopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38382529
DOI: 10.1016/j.ymthe.2024.02.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complementPMID 38382529Read ↗

Complement and Complement Targeting Therapies in Glomerular DiseasesSemantic proximity Read ↗

Targeted Complement Treatments in Glomerulopathies: A Comprehensive ReviewSemantic proximity Read ↗

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement systemSemantic proximity Read ↗

Complement in therapy and diseaseSemantic proximity Read ↗

The complement system in IgAN: mechanistic context for therapeutic opportunitiesSemantic proximity Read ↗

Antibody‐mediated complement activation in pathology and protectionSemantic proximity Read ↗

Truncated Complement Factor H Y402 Gene Therapy Cures C3 GlomerulonephritisSemantic proximity Read ↗

Targeting complement in IgA nephropathySemantic proximity Read ↗

Complement inhibition in C3 glomerulopathy.Semantic proximity Read ↗

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.Semantic proximity Read ↗

C3 Glomerulopathy: A Current Perspective in an Evolving LandscapeSemantic proximity Read ↗

Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.